Plain-English translation of NCT04699604 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested whether a specific skin response pattern could help doctors predict which children with allergic asthma would benefit from taking Levocetirizine (an over-the-counter antihistamine) in addition to their regular asthma medicines. About 300 children ages 6 to 17 participated over 17 weeks. Half received the medication and half received a placebo (inactive treatment) while researchers measured how well their asthma control improved.
Currently, doctors prescribe asthma treatments by trial and error, without knowing in advance which children will actually benefit from adding an antihistamine. This trial aimed to develop a simple skin test that could predict treatment response ahead of time, so doctors could make smarter treatment choices for children with allergic asthma.
Participants attended multiple visits over about 4 months. At the first visit, researchers performed a special skin test on the forearm using histamine and a laser to measure skin response. Children then took either the antihistamine medication or a matching placebo liquid by mouth daily while continuing their regular asthma medicines. They returned for follow-up visits at 2, 3, and 4 weeks to have their blood drawn and complete asthma control questionnaires to track whether their asthma improved.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States
Phase
Large-scale testing
Sponsor
Bridgette Jones
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Enrollment target
~55 participants
Started
April 2021
Primary completion
April 2026
Age range
6 Years – 17 Years
Last updated on clinicaltrials.gov in July 2026.